2013
Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors
Aziz SA, Sznol JA, Adeniran A, Parisi F, Kluger Y, Camp RL, Kluger HM. Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors. BMC Clinical Pathology 2013, 13: 3. PMID: 23374878, PMCID: PMC3575219, DOI: 10.1186/1472-6890-13-3.Peer-Reviewed Original ResearchRenal cell carcinoma tumorsMetastatic tumorsCarcinoma tumorsMetastatic specimensPredictive biomarker developmentFGF-R1Predictive biomarker testingRenal cell carcinomaTissue microarray blocksResultsNo significant differencesKi67-positive cellsMore Ki67-positive cellsSignificant differencesCell carcinomaBiomarker testingPDGF-RβMicroarray blocksPositive cellsQuantitative immunofluorescence methodVEGF-R3VEGF-R1Expression of targetsTumorsImmunofluorescence methodPrimary specimens
2010
A Role for ATF2 in Regulating MITF and Melanoma Development
Shah M, Bhoumik A, Goel V, Dewing A, Breitwieser W, Kluger H, Krajewski S, Krajewska M, DeHart J, Lau E, Kallenberg DM, Jeong H, Eroshkin A, Bennett DC, Chin L, Bosenberg M, Jones N, Ronai ZA. A Role for ATF2 in Regulating MITF and Melanoma Development. PLOS Genetics 2010, 6: e1001258. PMID: 21203491, PMCID: PMC3009656, DOI: 10.1371/journal.pgen.1001258.Peer-Reviewed Original ResearchConceptsMelanoma developmentMouse melanoma modelHuman melanoma cell linesMITF expressionMelanoma tissue microarrayMelanoma cell linesMetastatic diseasePoor prognosisTissue microarrayXenograft modelMelanoma modelPrimary specimensPrimary human melanocytesOncogenic BRAFMiceGene expression profilingHigh MITF expressionDependent suppressionATF2 knockdownCell linesSoft agarHuman melanocytesMelanocytesMelanoma susceptibilityPrimary melanocytes
2007
VEGF, VEGFR1, and VEGFR2 expression in melanoma
Mehnert J, McCarthy M, Aziz S, Sznol M, Flaherty K, Camp R, Rimm D, Kluger H. VEGF, VEGFR1, and VEGFR2 expression in melanoma. Journal Of Clinical Oncology 2007, 25: 8520-8520. DOI: 10.1200/jco.2007.25.18_suppl.8520.Peer-Reviewed Original ResearchPrimary specimensR2 expressionAssessment of PI3 kinase as a druggable target in melanoma
Aziz S, Pick-Golan E, McCarthy M, Flaherty K, Camp R, Rimm D, Kluger H. Assessment of PI3 kinase as a druggable target in melanoma. Journal Of Clinical Oncology 2007, 25: 8521-8521. DOI: 10.1200/jco.2007.25.18_suppl.8521.Peer-Reviewed Original ResearchPI3-kinaseKinase expressionDrug targetsIntracellular signal transduction pathwaysNumerous cellular functionsSignal transduction pathwaysMajor intracellular signal transduction pathwaysPI3-kinase inhibitorAttractive drug targetValuable drug targetsCellular functionsTransduction pathwaysDifferential expressionBenign neviKinaseDruggable targetsExpression levelsProtein levelsMalignant melanocytesKinase inhibitorsDisease aggressionExpressionMalignant cellsPrimary specimensTargetThe X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization
Kluger HM, McCarthy MM, Alvero AB, Sznol M, Ariyan S, Camp RL, Rimm DL, Mor G. The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. Journal Of Translational Medicine 2007, 5: 6. PMID: 17257402, PMCID: PMC1796544, DOI: 10.1186/1479-5876-5-6.Peer-Reviewed Original ResearchConceptsMetastatic melanomaXIAP expressionCell linesCy5-conjugated antibodiesMechanism of actionMelanoma cell linesPrimary lesionOvarian cancerTherapeutic approachesTissue microarrayDisease aggressionCarboplatin sensitivityChemotherapy resistanceMalignant progressionClinical specimensBenign counterpartsCarboplatinMelanomaChemotherapy sensitizationPrimary specimensPhenoxodiolResistant cellsMelanoma cellsHigh expressionMelanoma resistance